智飛生物(300122.SZ):重組新冠蛋白疫苗獲批附條件上市
格隆匯3月2日丨智飛生物(300122.SZ)公佈,公司今日從國家藥品監督管理局(以下簡稱“國家藥監局”)官方網站查詢獲悉,由公司全資子公司安徽智飛龍科馬生物製藥有限公司(以下簡稱“智飛龍科馬”)與中國科學院微生物研究所(以下簡稱“中科院微生物所”)合作研發的重組新型冠狀病毒蛋白疫苗(CHO細胞)(以下簡稱“重組新冠蛋白疫苗”、“該疫苗”)獲批附條件上市。
重組新型冠狀病毒蛋白疫苗(CHO細胞)由中科院微生物所和公司全資子公司智飛龍科馬合作研發,該疫苗採用重組蛋白技術路線,在符合臨牀試驗方案的人羣中具有很好的安全性和防病效果。
重組新冠蛋白疫苗是首個獲批的重組新冠病毒蛋白疫苗,適用於預防新型冠狀病毒感染所致的疾病(COVID-19)。公司將持續做好該疫苗產品保質保量生產、供應等工作,若後續工作進展順利,將對該疫苗的WHO認證及其作為序貫(異源)加強針免疫接種起到促進作用,對上市公司未來業績、研發進展、國際化戰略推進也將產生一定的積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.